The Impact of Thalassemia and Sickle Cell Anemia
The bone marrow transplant Market is seeing increasing use for the treatment of non-malignant genetic disorders, such as thalassemia and sickle cell anemia. For many years, these conditions were managed with supportive care, but BMT is now being recognized as a potentially curative treatment. This is expanding the market's indications and its overall patient base.
The success of BMT in treating these genetic disorders is creating a new area of growth and is driving research into how to make the procedure safer and more accessible for these patients. As more people are diagnosed with these conditions, the demand for BMT is expected to grow, creating a significant opportunity for market players.
16 Views